These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34405958)

  • 41. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab.
    Miele E; Markowitz JE; Mamula P; Baldassano RN
    J Pediatr Gastroenterol Nutr; 2004 May; 38(5):502-8. PubMed ID: 15097438
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease.
    Friesen CA; Calabro C; Christenson K; Carpenter E; Welchert E; Daniel JF; Haslag S; Roberts CC
    J Pediatr Gastroenterol Nutr; 2004 Sep; 39(3):265-9. PubMed ID: 15319627
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up.
    Caviglia R; Ribolsi M; Rizzi M; Emerenziani S; Annunziata M; Cicala M
    World J Gastroenterol; 2007 Oct; 13(39):5238-44. PubMed ID: 17876895
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term Outcomes After Switching to CT-P13 in Pediatric-Onset Inflammatory Bowel Disease: A Single-Center Prospective Observational Study.
    Kang B; Lee Y; Lee K; Choi YO; Choe YH
    Inflamm Bowel Dis; 2018 Feb; 24(3):607-616. PubMed ID: 29390113
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic Drug Monitoring-guided High-dose Infliximab for Infantile-onset Inflammatory Bowel Disease: A Case Series.
    Assa A; Dorfman L; Shouval DS; Shamir R; Cohen S
    J Pediatr Gastroenterol Nutr; 2020 Oct; 71(4):516-520. PubMed ID: 32639454
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit.
    Alten R; An Y; Kim DH; Yoon S; Peyrin-Biroulet L
    Clin Drug Investig; 2022 Jun; 42(6):477-489. PubMed ID: 35657560
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease: what is the opportunity cost of improving access to healthcare?
    Hilley P; Wong D; Ma R; Peterson A; De Cruz P
    Intern Med J; 2024 Jun; 54(6):970-979. PubMed ID: 38214034
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease.
    Grišić AM; Dorn-Rasmussen M; Ungar B; Brynskov J; Ilvemark JFKF; Bolstad N; Warren DJ; Ainsworth MA; Huisinga W; Ben-Horin S; Kloft C; Steenholdt C
    United European Gastroenterol J; 2021 Feb; 9(1):91-101. PubMed ID: 33079627
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
    Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
    Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.
    Cohen RD
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S17-22. PubMed ID: 11380038
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries.
    Yoo HK; Byun HG; Caprioli F; Fumery M; Peyrin-Biroulet L; Sreedhar S; Potter J; Jang M
    BMC Health Serv Res; 2022 Nov; 22(1):1319. PubMed ID: 36333704
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rapid Infliximab Infusion in Children: A Multicenter Retrospective Cohort Study.
    Lev-Tzion R; Assa A; Yerushalmi B; Lahad A; Friedman M; Ledder O; Turner D
    J Pediatr Gastroenterol Nutr; 2017 Nov; 65(5):e101-e103. PubMed ID: 29064928
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevention of acute adverse events related to infliximab infusions in pediatric patients.
    Lahdenne P; Wikström AM; Aalto K; Kolho KL
    Arthritis Care Res (Hoboken); 2010 Jun; 62(6):785-90. PubMed ID: 20535789
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacist-Driven Therapeutic Infliximab Monitoring at the Point of Care Using Rapidly Assessed Drug Levels in Patients with Inflammatory Bowel Disease.
    Rentsch CA; Ward MG; Luber RP; Taylor KM; Gibson DJ; Headon B; Rosella O; Su HY; Friedman AB; Dooley M; Sparrow MP; Gibson PR
    Ther Drug Monit; 2023 Jun; 45(3):383-391. PubMed ID: 36174193
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Short article: The effect of implementation of a treatment algorithm for infliximab on remission rates and drug costs in inflammatory bowel disease patients.
    Taks M; Pijls PA; Derijks LJ; Ten Broeke R; Grouls RJ; Curvers J; Gilissen LP
    Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):169-173. PubMed ID: 27749780
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inflammatory bowel disease patients are frequently nonadherent to scheduled induction and maintenance infliximab therapy: A Canadian cohort study.
    Ma C; Evaschesen CJ; Gracias G; Huang VW; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    Can J Gastroenterol Hepatol; 2015; 29(6):309-14. PubMed ID: 26069894
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy.
    Armuzzi A; Fiorino G; Variola A; Manetti N; Fries W; Orlando A; Maconi G; Bossa F; Cappello M; Biancone L; Cantoro L; Costa F; D'Incà R; Lionetti P; Principi M; Castiglione F; Annunziata ML; Di Sabatino A; Di Girolamo M; Terpin MM; Cortelezzi CC; Saibeni S; Amato A; Ardizzone S; Guidi L; Danese S; Massella A; Ventra A; Rizzuto G; Massari A; Perri F; Annese V;
    Inflamm Bowel Dis; 2019 Feb; 25(3):568-579. PubMed ID: 30137352
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening.
    Ben-Shatach Z; Ziv-Baran T; Fudim E; Yavzori M; Picard O; Levartovsky A; Selinger L; Weiss B; Kopylov U; Eliakim R; Ungar B
    Therap Adv Gastroenterol; 2022; 15():17562848221083395. PubMed ID: 35646158
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Infliximab therapy in children and adolescents with inflammatory bowel disease.
    Veres G; Baldassano RN; Mamula P
    Drugs; 2007; 67(12):1703-23. PubMed ID: 17683171
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.
    Papamichael K; Chachu KA; Vajravelu RK; Vaughn BP; Ni J; Osterman MT; Cheifetz AS
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1580-1588.e3. PubMed ID: 28365486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.